Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PG110 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lowest dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Second dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Third dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Fourth dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Fifth dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Top dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Placebo | EXPERIMENTAL | single, slow intravenous infusion that matches PG110 in appearance |
| Seventh Dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Eight Dose of PG110 | EXPERIMENTAL | single, slow intravenous infusion |
| Name | Type | Description |
|---|---|---|
| PG110 | BIOLOGICAL | Single, slow intravenous infusion |
| Placebo | BIOLOGICAL | Single, slow intravenous infusion that matches PG110 in appearance |
Inclusion Criteria: * Moderate to severe pain attributed to knee osteoarthritis Exclusion Criteria: * Significant comorbidity * Significant pain states other than osteoarthritis * Concomitant medications that might affect assessments
PG110 is an investigational monoclonal antibody being studied for the treatment of pain associated with osteoarthritis of the knee. It is administered to patients with knee osteoarthritis to evaluate its safety and tolerability. The drug is currently in Phase 1 clinical development and is not yet approved for use.
PG110 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is an investigational monoclonal antibody in Phase 1 clinical development for knee osteoarthritis pain. Abbott Laboratories is conducting clinical trials to evaluate the safety and tolerability of PG110.
PG110 is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 56 participants with knee osteoarthritis pain. The study was randomized, double-blind, and controlled. PG110 is an investigational drug and has not been approved by regulatory authorities.
PG110 has one completed clinical trial, identified as NCT00941746, titled "Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain." This Phase 1 study enrolled 56 participants with knee osteoarthritis in the Netherlands. The trial was randomized, double-blind, and controlled, and it has been completed.
PG110 is a monoclonal antibody being developed by Abbott Laboratories for knee osteoarthritis pain. No alternative names for PG110 have been reported in clinical trial registries. The drug is currently in Phase 1 development, and its safety and tolerability were evaluated in a completed clinical trial.